BC Innovations | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
BC Week In Review | Dec 21, 2018
Financial News

Annexon to use $75M series C to advance complement inhibitors to Phase II

Annexon Biosciences Inc. (South San Francisco, Calif.) raised $75 million in a series C round on Dec. 19 that the company said will fund development of its lead complement inhibitors through several clinical stages. Annexon...
BC Extra | Dec 19, 2018
Financial News

Annexon to use $75M series C to advance complement inhibitors to Phase II

Annexon Biosciences Inc. (South San Francisco, Calif.) raised $75 million in a series C round on Wednesday that the company said will fund development of its lead complement inhibitors through several clinical stages. Annexon is...
BC Extra | Jun 24, 2016
Financial News

Annexon raises $44M in B round

Annexon Biosciences Inc. (South San Francisco, Calif.) raised $44 million in a series B round led by new investor New Enterprise Associates. New investor Correlation Ventures also participated, as did existing investors including Novartis Venture...
Items per page:
1 - 4 of 4